Concerning the targeted therapies, the most prevalent genomic driver event in NSCLC is activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) in about 25 to 30% of non–squamous-cell NSCLCs in Western countries [7]. Here, KRAS is linked to non-small cell lung carcinoma.